TIPS for treatment of refractory ascites in cirrhosis

Lanjing WANG; Xin YAO; Jianping QIN; Shanhong TANG

doi:10.3969/j.issn.1001-5256.2022.11.034

Volume 38 Issue 11

Nov. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(11): 2606-2610

PDF( 1882 KB)

TIPS for treatment of refractory ascites in cirrhosis

DOI: 10.3969/j.issn.1001-5256.2022.11.034

Lanjing WANG^{1, 2},
Xin YAO¹,
Jianping QIN¹,
Shanhong TANG^{1, 2
,
,
,}

1.
Department of Gastroenterology, The General Hospital of Western Theater Command, Chengdu 610083, China
2.
Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646099, China

Research funding:

Scientific Research Project of Sichuan Provincial Health Commission (20PJ180)

More Information

Corresponding author: TANG Shanhong, 15928956390@163.com(ORCID: 0000-0001-6652-2942)
Received Date: 2022-03-22
Accepted Date: 2022-05-07
Published Date: 2022-11-20

Abstract

Abstract

Refractory ascites (RA) is one of the complications of portal hypertension in decompensated cirrhosis. It is hard to treat RA and there is high mortality in patients with RA. Nowadays, Transjugular Intrahepatic Portosystemic Shunt (TIPS) is used as a second-line treatment for RA. TIPS can improve the clinical symptoms of ascites by reducing the pressure of portal vein. Accumulated studies have proposed that applications of polytetrafluoroethylene covered stents and careful selection of applied patients can improve the prognosis of RA patients. Therefore, some scholars propose that TIPS can be used as one of the first-line treatments for RA. This review will comprehensively summarize current understanding of TIPS in treating RA patients and elaborate the most recently updated progress of the relevant researches, aiming to promote the development of studies on using TIPS as a treatment for RA patients in China.
- Liver Cirrhosis,
- Ascites,
- Portasystemic Shunt, Transjugular Intrahepatic,
- Hypertension, Portal

FullText(HTML)

References(37)

References

[1]	NEONG SF, ADEBAYO D, WONG F. An update on the pathogenesis and clinical management of cirrhosis with refractory ascites[J]. Expert Rev Gastroenterol Hepatol, 2019, 13(4): 293-305. DOI: 10.1080/17474124.2018.1555469.
[2]	AITHAL GP, PALANIYAPPAN N, CHINA L, et al. Guidelines on the management of ascites in cirrhosis[J]. Gut, 2021, 70(1): 9-29. DOI: 10.1136/gutjnl-2020-321790.
[3]	LARRUE H, VINEL JP, BUREAU C. Management of severe and refractory ascites[J]. Clin Liver Dis, 2021, 25(2): 431-440. DOI: 10.1016/j.cld.2021.01.010.
[4]	MØLLER S, BENDTSEN F. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis[J]. Liver Int, 2018, 38(4): 570-580. DOI: 10.1111/liv.13589.
[5]	ADEBAYO D, NEONG SF, WONG F. Refractory ascites in liver cirrhosis[J]. Am J Gastroenterol, 2019, 114(1): 40-47. DOI: 10.1038/s41395-018-0185-6.
[6]	Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of ascites and complications in cirrhosis[J]. J Clin Hepatol, 2017, 33(10): 1847-1863. DOI: 10.3969/j.issn.1001-5256.2017.10.003. 中华医学会肝病学分会. 肝硬化腹水及相关并发症的诊疗指南[J]. 临床肝胆病杂志, 2017, 33(10): 1847-1863. DOI: 10.3969/j.issn.1001-5256.2017.10.003.
[7]	D'AMICO G, MORABITO A, D'AMICO M, et al. Clinical states of cirrhosis and competing risks[J]. J Hepatol, 2018, 68(3): 563-576. DOI: 10.1016/j.jhep.2017.10.020.
[8]	de FRANCHIS R, Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63(3): 743-752. DOI: 10.1016/j.jhep.2015.05.022.
[9]	GARCÍA-PAGÁN JC, SAFFO S, MANDORFER M, et al. Where does TIPS fit in the management of patients with cirrhosis?[J]. JHEP Rep, 2020, 2(4): 100122. DOI: 10.1016/j.jhepr.2020.100122.
[10]	Chinese College of Interventionalists. CCI clinical practice guidelines: Management of TIPS for portal hypertension (2019 edition)[J]. J Clin Hepatol, 2019, 35(12): 2694-2699. DOI: 10.3969/j.issn.1001-5256.2019.12.010. 中国医师协会介入医师分会. 中国门静脉高压经颈静脉肝内门体分流术临床实践指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2694-2699. DOI: 10.3969/j.issn.1001-5256.2019.12.010.
[11]	QIN JP, TANG W, TANG SH, et al. Modified transjugular intrahepatic portosystemic shunt in the treatment of portal hypertension of liver cirrhosis[J]. Chin J Dig, 2014, 34(1): 33-36. DOI: 10.3760/cma.j.issn.0254-1432.2014.01.012. 秦建平, 唐文, 汤善宏, 等. 改良经颈静脉肝内门体静脉分流术治疗肝硬化门静脉高压症[J]. 中华消化杂志, 2014, 34(1): 33-36. DOI: 10.3760/cma.j.issn.0254-1432.2014.01.012.
[12]	TANG SH, QIN JP, SHU QF, et al. The imaging guidance for the portal vein branch puncturing in performing TIPS: recent progress in research[J]. J Intervent Radiol, 2014, 23(7): 640-643. DOI: 10.3969/j.issn.1008-794X.2014.07.022. 汤善宏, 秦建平, 束庆飞, 等. TIPS术中引导门静脉分支穿刺方法[J]. 介入放射学杂志, 2014, 23(7): 640-643. DOI: 10.3969/j.issn.1008-794X.2014.07.022.
[13]	BIGGINS SW, ANGELI P, GARCIA-TSAO G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2021, 74(2): 1014-1048. DOI: 10.1002/hep.31884.
[14]	ARROYO V, GINÈS P, GERBES AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club[J]. Hepatology, 1996, 23(1): 164-176. DOI: 10.1002/hep.510230122.
[15]	SUN MY, TANG SH, ZENG WZ. An excerpt of 2017 KASL clinical practice guidelines for fiver cirrhosis: Ascites and related complications[J]. J Clin Hepatol, 2018, 34(9): 1877-1878. DOI: 10.3969/j.issn.1001-5256.2018.09.010. 孙梦滢, 汤善宏, 曾维政. 《2017年韩国肝病学会临床实践指南: 肝硬化-腹水及相关并发症》摘译[J]. 临床肝胆病杂志, 2018, 34(9): 1877-1878. DOI: 10.3969/j.issn.1001-5256.2018.09.010.
[16]	FUKUI H, SAITO H, UENO Y, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2015[J]. J Gastroenterol, 2016, 51(7): 629-650. DOI: 10.1007/s00535-016-1216-y.
[17]	ZHANG X, WANG SZ, ZHENG JF, et al. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients[J]. World J Gastroenterol, 2014, 20(32): 11400-11405. DOI: 10.3748/wjg.v20.i32.11400.
[18]	BOIKE JR, THORNBURG BG, ASRANI SK, et al. North American practice-based recommendations for transjugular intrahepatic portosystemic shunts in portal hypertension[J]. Clin Gastroenterol Hepatol, 2022, 20(8): 1636-1662. DOI: 10.1016/j.cgh.2021.07.018.
[19]	de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno VⅡ-Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4): 959-974. DOI: 10.1016/j.jhep.2021.12.022.
[20]	BOSCH J. Small diameter shunts should lead to safe expansion of the use of TIPS[J]. J Hepatol, 2021, 74(1): 230-234. DOI: 10.1016/j.jhep.2020.09.018.
[21]	BUREAU C, THABUT D, OBERTI F, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites[J]. Gastroenterology, 2017, 152(1): 157-163. DOI: 10.1053/j.gastro.2016.09.016.
[22]	TAN HK, JAMES PD, SNIDERMAN KW, et al. Long-term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion[J]. J Gastroenterol Hepatol, 2015, 30(2): 389-395. DOI: 10.1111/jgh.12725.
[23]	PARVINIAN A, BUI JT, KNUTTINEN MG, et al. Transjugular intrahepatic portosystemic shunt for the treatment of medically refractory ascites[J]. Diagn Interv Radiol, 2014, 20(1): 58-64. DOI: 10.5152/dir.2013.13131.
[24]	SALERNO F, CAMMÀ C, ENEA M, et al. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data[J]. Gastroenterology, 2007, 133(3): 825-834. DOI: 10.1053/j.gastro.2007.06.020.
[25]	SRINIVASA RN, SRINIVASA RN, CHICK J, et al. Transjugular intrahepatic portosystemic shunt reduction using the GORE VIATORR controlled expansion endoprosthesis: Hemodynamics of reducing an established 10-mm TIPS to 8-mm in diameter[J]. Cardiovasc Intervent Radiol, 2018, 41(3): 518-521. DOI: 10.1007/s00270-017-1807-x.
[26]	MIRAGLIA R, MARUZZELLI L, DI PIAZZA A, et al. Transjugular intrahepatic portosystemic shunt using the new gore viatorr controlled expansion endoprosthesis: Prospective, single-center, preliminary experience[J]. Cardiovasc Intervent Radiol, 2019, 42(1): 78-86. DOI: 10.1007/s00270-018-2040-y.
[27]	TREBICKA J, BASTGEN D, BYRTUS J, et al. Smaller-diameter covered transjugular intrahepatic portosystemic shunt stents are associated with increased survival[J]. Clin Gastroenterol Hepatol, 2019, 17(13): 2793-2799. e1. DOI: 10.1016/j.cgh.2019.03.042.
[28]	PIEPER CC, JANSEN C, MEYER C, et al. Prospective evaluation of passive expansion of partially dilated transjugular intrahepatic portosystemic shunt stent grafts-A three-dimensional sonography study[J]. J Vasc Interv Radiol, 2017, 28(1): 117-125. DOI: 10.1016/j.jvir.2016.06.023.
[29]	European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69(2): 406-460. DOI: 10.1016/j.jhep.2018.03.024.
[30]	SCHEPIS F, VIZZUTTI F, GARCIA-TSAO G, et al. Under-dilated TIPS associate with efficacy and reduced encephalopathy in a prospective, non-randomized study of patients with cirrhosis[J]. Clin Gastroenterol Hepatol, 2018, 16(7): 1153-1162. e7. DOI: 10.1016/j.cgh.2018.01.029.
[31]	BAI M, QI XS, YANG ZP, et al. TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis[J]. World J Gastroenterol, 2014, 20(10): 2704-2714. DOI: 10.3748/wjg.v20.i10.2704.
[32]	BUCSICS T, HOFFMAN S, GRVNBERGER J, et al. ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis[J]. Liver Int, 2018, 38(6): 1036-1044. DOI: 10.1111/liv.13615.
[33]	SHEN NT, SCHNEIDER Y, CONGLY SE, et al. Cost effectiveness of early insertion of transjugular intrahepatic portosystemic shunts for recurrent ascites[J]. Clin Gastroenterol Hepatol, 2018, 16(9): 1503-1510. e3. DOI: 10.1016/j.cgh.2018.03.027.
[34]	POSE E, CARDENAS A. Translating our current understanding of ascites management into new therapies for patients with cirrhosis and fluid retention[J]. Dig Dis, 2017, 35(4): 402-410. DOI: 10.1159/000456595.
[35]	ALLEGRETTI AS, ORTIZ G, CUI J, et al. Changes in kidney function after transjugular intrahepatic portosystemic shunts versus large-volume paracentesis in cirrhosis: A matched cohort analysis[J]. Am J Kidney Dis, 2016, 68(3): 381-391. DOI: 10.1053/j.ajkd.2016.02.041.
[36]	YAO X, ZHOU H, HUANG S, et al. Effects of transjugular intrahepatic portosystemic shunt using the Viatorr stent on hepatic reserve function in patients with cirrhosis[J]. World J Clin Cases, 2021, 9(7): 1532-1542. DOI: 10.12998/wjcc.v9.i7.1532.
[37]	QIN JP, TANG SH, JIANG MD, et al. Contrast enhanced computed tomography and reconstruction of hepatic vascular system for transjugular intrahepatic portal systemic shunt puncture path planning[J]. World J Gastroenterol, 2015, 21(32): 9623-9629. DOI: 10.3748/wjg.v21.i32.9623.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (449) PDF downloads(56)

TIPS for treatment of refractory ascites in cirrhosis

DOI: 10.3969/j.issn.1001-5256.2022.11.034

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

TIPS for treatment of refractory ascites in cirrhosis

DOI: 10.3969/j.issn.1001-5256.2022.11.034

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content